Compare Amylx Pharmaceuticals Inc (AMLX) vs Iris Energy Limited (IREN) Price & Performance

AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.

The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.

IREN trades at $41.11, down 1.46% on the day, amid a bearish technical signal with key support at $40. The company is transitioning from Bitcoin mining to AI infrastructure, with revenue growing from $501M in 2025 to a projected $757M in 2026. Recent earnings have missed expectations, but analyst sentiment remains largely positive with a consensus price target of $79.11, representing significant upside potential from current levels.

The outlook hinges on successful execution of its AI cloud strategy, with a $3.1B contracted ARR target by end-2026 being a key catalyst. However, risks include intense competition, high capital expenditure evidenced by negative investing cash flow, and recent earnings misses. The stock offers high growth potential but carries substantial execution risk.